Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 7/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | BRAF | P15056 | 12/20 | 0.49 |
| ▸ | RAF1 | P04049 | 10/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831556 | 0.90 | CSF1R (0.58) | CSF1RMAPK14BRAFRAF1LYN | |
| SCHEMBL4829551 | 0.86 | CSF1R (0.56) | CSF1RMAPK14BRAFRAF1LYN | |
| Morpholine SCHEMBL27557468 | 0.86 | BRAF (0.46) | CSF1RMAPK14BRAFRAF1 | |
| SCHEMBL4827733 | 0.85 | CSF1R (0.65) | CSF1RMAPK14BRAFRAF1LYN | |
| SCHEMBL4833606 | 0.84 | MAPK14 (0.58) | MAPK14BRAFRAF1 | |
| SCHEMBL4829468 | 0.83 | CSF1R (0.59) | CSF1RMAPK14BRAFRAF1LYN | |
| SCHEMBL7828486 | 0.81 | CSF1R (0.47) | CSF1RMAPK14BRAFRAF1LYN | |
| SCHEMBL4831830 | 0.78 | MAPT (0.40) | CSF1RMAPK14 | |
| SCHEMBL6084723 | 0.78 | MAPK14 (0.58) | MAPK14BRAFRAF1 | |
| SCHEMBL7823001 | 0.78 | CSF1R (0.45) | CSF1RMAPK14BRAFRAF1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | CSF1R 873/4885MAPK14 2834/4885BRAF 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.